AMPEL BioSolutions i aso nei o loʻo faʻasalalau se faʻalavelave i le saʻo ma le faʻapitoa o vailaʻau e mafai ona suia ai le auala e togafitia ai e fomaʻi faʻamaʻi paʻu, e pei ole Lupus, Psoriasis, Atopic Dermatitis ma Scleroderma. Faʻaalia i totonu o le tusi talaaga a le tupulaga Science Advances, o loʻo faʻamatalaina e le pepa le auala e aʻoaʻoina ai masini faʻapitoa a le AMPEL e faʻaalia ai gaioiga faʻamaʻi mai faʻamatalaga faʻamatalaga faʻamatalaga na maua mai biopsies paʻu maʻi. O le su'ega a le fale su'esu'e, ua na'o se manatu mo nai tausaga ua tuana'i, ua sauni nei mo le atina'e mo le fa'aaogaina. O le taulaiga muamua a le AMPEL o le Lupus, ae o le suʻega e mafai ona faʻaogaina mo le tele o faʻamaʻi paʻu autoimmune poʻo le afaina e aafia ai le sili atu i le 35 miliona Amerika.
Ole auala fou ole a'oa'oina ole masini a le AMPEL, lea ua sauni nei e fa'atupuina e avea o se su'esu'ega biomarker lagolago, e mafai ona matua a'afia ai le tausiga o le soifua maloloina e ala i le fa'atagaina o foma'i e fa'ailoa le mafua'aga o fa'ama'i fa'ama'i ma filifili lelei togafitiga talafeagai. O le auala a le AMPEL e lava le maaleale e iloa ai suiga i le falemaʻi e leʻi aʻafia i le paʻu ina ia vave faʻaogaina e mafai ona puipuia ai faʻamaʻi afi ma faʻaleagaina paʻu e aliali mai i faʻamaʻi. Ole fa'aogaina ole a'oa'oga masini a le AMPEL e mafai fo'i ona fesoasoani i kamupani fa'afoma'i ile atina'eina o vaila'au ma su'esu'ega ile falema'i.
O tagata mama'i o lo'o maua i fa'ama'i fa'ama'i fa'ama'i e masani ona maua i fa'ama'i fa'alavelave e a'afia ai gaioiga i aso uma e pei o galuega ma olaga faaleaiga. Talu ai o faʻailoga e leʻi faʻamoemoeina e masani ona iʻu ai i malaga i le Potu Faʻafuaseʻi, o le mafai ona vavalo faʻamaʻi faʻaleagaina ma faʻalavelave faʻapitoa i biopsies paʻu masani e taua tele le tausiga o le soifua maloloina ma le tamaoaiga o le soifua maloloina.
Fa'atasi ma le paipa a le AMPEL o mea faigaluega e fa'avasega ai fa'amaumauga fa'apitoa tele ma lavelave ("Big Data"), o le polokalame a'oa'oga masini a le AMPEL o se la'asaga taua lea i le fa'atinoina o se su'ega masani o le pa'u mo le mata'ituina o gaioiga fa'ama'i ma tu'uina atu le lagolago fa'ai'uga mo togafitiga e fa'atatau i le kenera o le ma'i. fa'aaliga. O lenei mea o le a suia ai le auala e togafitia ai e fomaʻi faʻamaʻi faʻamaʻi paʻu e ala i le faʻaaogaina o faʻamatalaga na aoina mai i le suʻega suʻesuʻe ma suʻesuʻeina e ala i le aʻoaʻoina o masini e suʻesuʻe ai, faʻamaonia le faʻalavelave mole mole saʻo ma togafitia faʻamaʻi paʻu aʻo leʻi amataina le faʻaleagaina, faʻaolaina tagata gasegase mai le tiga ma le faʻalavelave o se faʻamaʻi. a le o lea e matua afaina ai o latou olaga.
E fa'ata'ita'i e kamupani fa'afoma'i vaila'au i fa'ata'ita'iga a le falema'i ma feagai ma le lu'itau o le lesitalaina o tagata mama'i o lo'o i ai le malosi sili e tali atu ai i togafitiga o lo'o fa'ata'ita'iina. O le lesitalaina o ma'i "sese" e mafai ona i'u ai i le fa'aletonu o le fa'amasinoga, e masani ona fa'aleaogaina ai le atina'eina o se vaila'au aga'i i le fa'amaoniga a le FDA e ono maua ai se manuia i se vaega la'ititi o le aofa'i o tagata ma'i. Ole su'ega ole pa'u ole AMPEL ole a fesoasoani i kamupani fa'afoma'i e iloa ai tagata mama'i e ono tali atu i togafitiga fa'apitoa, ma fesoasoani e fa'aleleia taunu'uga ile fa'ata'ita'iga ile falema'i.
Dr. Peter Lipsky, Ofisa Sili o Fomaʻi ma Co-Founder, AMPEL BioSolutions: "E leai se isi faʻaoga i le taimi nei e mafai ona vaʻai saʻo le gaioiga o faʻamaʻi ma tuʻuina atu togafitiga talafeagai, ma e matua faʻamalosia i matou i lenei faʻalavelave na lipotia i le Science Advances. Mo tagata mama'i o lo'o maua i fa'ama'i fa'ama'i tumau, e le mafai ona vave o'o mai se fa'afouga anoa i togafitiga. I le maeʻa ai o le atinaʻeina o le matou masini aʻoaʻoga manatu, ua mafai nei ona matou agai i luma i le galulue faatasi ma a matou paaga e atiaʻe lenei suʻega paʻu e mafai ona suia le auala e mafai ai e fomaʻi ona fesoasoani i tagata mamaʻi e maua i faʻamaʻi faʻamaʻi paʻu e pulea o latou tulaga e ala i le ofoina atu o togafitiga sili atu ma saʻo e faʻatatau i tagata taʻitoʻatasi. fa'amatalaga ma'i nai lo se faiga lautele."
Dr. Amrie Grammer, Ofisa Sili Fa'asaienisi ma Fa'avae Fa'atasi, AMPEL BioSolutions: "" Ua fausia e le matou 'au se meafaigaluega e mafai ona suia ai le auala e togafitia ai tagata mama'i e maua i le pa'u. I le avea ai o se kamupani vailaʻau saʻo, AMPEL o loʻo suia le faʻataʻitaʻiga o togafitiga i faʻamaʻi faʻamaʻi ma faʻamaʻi. Matou te mitamita i le faia o lenei galuega i Virginia ma o le a faʻaauau pea ona faʻafaigaluegaina taleni ma faʻalauteleina a matou pisinisi iinei.
Dr. Wright Caughman, Polofesa, Matagaluega o Dermatology, Emory School of Medicine, ma le Exec VP mo Mataupu tau Soifua Maloloina (Emeritus), Iunivesite o Emory: "O le suʻega o le biopsy paʻu sili ona fou a le AMPEL o le a maua ai se meafaigaluega fou sili mo le suʻesuʻeina ma le puleaina o le autoimmune ma fa'ama'i mumu o le pa'u. AMPEL o loʻo tuʻuina atu lenei galuega i le Sosaiete mo Suʻesuʻega Dermatology fonotaga mulimuli ane i lenei masina. O le taimi lava e fa'amaonia ai e le CLIA le su'ega genomic a le AMPEL, o le a mafai loa e foma'i ona fa'ailoa vave vaila'au sili mo ma'i ta'ito'atasi ma maua vave ma saogalemu le pulea o latou fa'ama'i.
OA MEA E AVEA MAI LENEI TUSI:
- This will transform the way doctors treat chronic skin diseases by using the information gathered by the lab test and analyzed by machine learning to diagnose, characterize the precise molecular abnormalities and treat skin diseases before damage begins, saving patients from pain and inconvenience of a disease that otherwise drastically affects their lives.
- Paired with AMPEL’s pipeline of tools to analyze very large and complex clinical datasets (“Big Data”), AMPEL’s machine learning program is a significant step towards implementing a routine skin test for monitoring disease activity and providing decision support for treatment based on a patient’s gene expression.
- Following the development of our machine learning concept, we can now move forward in working with our partners to develop this skin test that could transform the way doctors can help patients with chronic skin disease manage their condition by offering better and more precise treatments based on individual patient data rather than a general approach.
